T2 Biosystems | 8-K: Disclosure Information of Public Offering in Compliance With Nasdaq Listing Rule 5550(b)(2)
T2 Biosystems | 8-K: Entry into a Securities Purchase Agreement
T2 Biosystems | 8-K: Current report
T2 Biosystems | 8-K: Amendment and Restatement Certificate of Designation of Preferences, Rights and Limitations of Convertible Preferred Stock
T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
T2 Biosystems | 8-K: T2 Biosystems Announces First Quarter 2024 Financial Results
T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
T2 Biosystems | S-1: General form for registration of securities under the Securities Act of 1933
T2 Biosystems | 8-K: Agreement of Debt Conversion Into Equity
T2 Biosystems | 8-K: Voting Results of Special Shareholders' Meeting
T2 Biosystems | 8-K: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
T2 Biosystems | 8-K: T2 Biosystems Announces T2Lyme Commercial Launch Plan, Provides Business Update
T2 Biosystems | 8-K: T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
T2 Biosystems | 8-K: T2 Biosystems Receives Extension to Comply With Nasdaq Listing Requirement
T2 Biosystems | DEF 14A: Definitive information statements
T2 Biosystems | 8-K: T2 Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results
T2 Biosystems | PRE 14A: Preliminary proxy statements relating to merger or acquisition
T2 Biosystems | 8-K: T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
T2 Biosystems | 8-K: T2 Biosystems Announces the Resignation of Thierry Bernard as Director II and All Committees of the Company's Board of Directors
T2 Biosystems | 8-K/A: Current report (Amendment)
No Data